Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T46360 Target Info
Target Name Opioid receptor sigma 1 (OPRS1)
Synonyms hSigmaR1; Sigma1R; Sigma1-receptor; Sigma non-opioid intracellular receptor 1; Sigma 1-type opioid receptor; SRBP; SR31747-binding protein; SR31747 binding protein 1; SR-BP; SIG-1R; Opioid receptor, sigma 1, isoform 1; OPRS1 protein; Aging-associated gene 8 protein; AAG8
Target Type Successful Target
Gene Name SIGMAR1
Biochemical Class GPCR rhodopsin
UniProt ID
SGMR1_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO199620928
Title Piperidine-Based Sigma Receptor Ligands.
Applicant(s) Australian Nuclear Science & Technology Organisation
Representative Drug(s) D0X5FS Drug Info Ki = 0.38 to 4.3 nM Click to Show More [1]
2 D0X9RA Drug Info Ki = 2.3 nM [1]
Patent ID WO2015132733
Title Use of Arylalkanolamines As Sigma-1 Receptor Antagonists.
Abstract The present invention relates to the use of arylalkanolamine compounds with sigma-1 receptor antagonist activity. In particular, the said arylalkanolamine compounds are useful in the treatment of conditions selected from the abuse of psychotropic substances such as cocaine or amphetamines, pain and cancer.
Applicant(s) Universita 'Degli Studi Di Pavia
Representative Drug(s) D0E9CK Drug Info Ki = 6.3 nM Click to Show More [1]
2 D07XVQ Drug Info N.A. [1]
Patent ID WO2008055932
Title 1,2,4-Triazole Derivatives As Sigma Receptor Inhibitors.
Abstract The invention relates to the use of compounds having pharmacological activity towards the sigma receptor, and more particularly to 1,2,4-triazole derivatives of formula (I) to processes of preparation of such compounds and to pharmaceutical compositions comprising them.
Applicant(s) Laboratorios Del Dr. Esteve
Representative Drug(s) D08RUG Drug Info N.A. Click to Show More [1]
2 D0MD6P Drug Info N.A. [1]
Patent ID WO200230422
Title Use of Defined Substances That Bind To The Sigma Receptor for Combating Sarcoma and Carcinoma.
Applicant(s) Merk Patent Gmbh
Representative Drug(s) D0J9SL Drug Info N.A. Click to Show More [1]
2 D0T5SO Drug Info N.A. [1]
Patent ID WO2015134545
Title Highly Selective Sigma Receptor Ligands and Radioligands As Probes In Nociceptive Processing and The Pathphysiological Study of Memory Deficits and Conitive Disorders.
Abstract A method for localizing and quantifying SIR role in nociceptive processing; for providing a guide to providing an analgesic therapy; of using an SIR selective ligand as a biomarker for pathphysiological study of memory deficits and cognitive disorders; or of detecting increased SIR density at the site of nerve injury arising from neuropathic pain comprising using as a probe at least one SRI selective compound or radioligand of the general formula III', or IV' :.
Applicant(s) The University of Mississippi
Representative Drug(s) D0DW1D Drug Info Ki = 2.5 pM [2]
Patent ID WO2013029057
Title Compositions and Methods for Treating Neurodegenerative Disease.
Abstract This invention relates to novel diarylamino compounds that bind to the sigma-2 receptor, to pharmaceutical compositions comprising such compounds, and to methods for inhibiting or restoring synapse loss in neuronal cells, modulating a membrane trafficking change in neuronal cells, and treating cognitive decline and neurodegenerative diseases and disorders therewith.
Applicant(s) Cognition Therapeutics, Inc
Representative Drug(s) D0SG9W Drug Info Ki = 110 nM [2]
Patent ID WO2011147910
Title Pyrazole Compounds As Sigma Receptor Inhibitors.
Abstract The invention refers to compounds of general formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved.
Applicant(s) Esteve Labor Dr
Representative Drug(s) D04PCA Drug Info N.A. [1]
Patent ID WO2010097641
Title Sigma Receptors Ligands with Anti-Apoptotic and/or Pro-Apoptotic Properties, Over Cellular Mechanisms, Exhibiting Prototypical Cytoprotective and Also Anticancer Activity.
Abstract The present invention involves new and original sigma receptors Iigands : (Mono-or dialkylaminoalkyl)- gama-butyrolactones, their analogues aminotetrahydroturanes, the (1-adamantyl) benzene alkylamines, the N,N Dialkyl alpha-[(adamantyl-1)benzyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or-alkyl phenylamines, their enantiomers or diastereoisomers, their pharmaceutically acceptable salts and Quinacrine Me-thylene blue, Astemizole and their relative analogues with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with prototypical anti-cancer, antimetastatic and antiviral activities associated with antagonism of the neuropatic pain and, at very low doses, with cytoprotectve and cytoregenerative activity against the cytodegenerative diseases.
Applicant(s) Vamvakides, Alexandre
Representative Drug(s) D0EO9Z Drug Info N.A. [1]
Patent ID WO2008087458
Title New Sigma-Receptor Ligands with Anti-Apoptotic and/or Pro-Apoptotic Properties Over Cellular Biochemical Mechanisms, with Neuroprotective, Anti-Cancer, Anti-Metastatic and Anti-(Chronic) Inflammatory Action.
Abstract The present invention involves new and original sigma receptors ligands : (Mono-or di-alkylaminoalkyl)- gama-butyrolactones, their analogues aminotetrahydrofuranes, the (1-adamantyl) phenyl(s) alkylamines, the N,N Dialkyl alpha-[(adamantyl-l)benzyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or-alkyl phenylamines, their enantiomers or diastereoisomers and their pharmaceutically acceptable salts, with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with anti-cancer, anti-metastatic, anti-(chronic) inflammatory, neuro-protective, anticonvulsive, antidepressive and nooanaleptic or sedative action.
Applicant(s) Vamvakides, Alexandre
Representative Drug(s) D0EO9Z Drug Info N.A. [1]
Patent ID WO9730983
Title Tetrahydro-N,N-Dimeti-Iyl-2,2-Diphenyl-3-Feranemetiianamine, Its Enantiomers, and Their Pharmaceutically Acceptable Acid Addition Salts.
Representative Drug(s) D0EO9Z Drug Info N.A. [1]
United States Patent and Trademark Office (USPTO)
Patent ID US8349898
Title Sigma1 Receptor Ligands and Methods of Use.
Applicant(s) Wisconsin Alumni Research Foundation
Representative Drug(s) D0A0DV Drug Info N.A. Click to Show More [1]
2 D0C1YW Drug Info N.A. [1]
3 D0G4GT Drug Info N.A. [1]
4 D0G7GN Drug Info N.A. [1]
5 D0L0CD Drug Info N.A. [1]
Patent ID US8946302
Title Selective Sigma-1 Receptor Ligands.
Representative Drug(s) D0A0DV Drug Info N.A. Click to Show More [1]
2 D0C1YW Drug Info N.A. [1]
3 D0G4GT Drug Info N.A. [1]
4 D0G7GN Drug Info N.A. [1]
5 D0L0CD Drug Info N.A. [1]
Patent ID US20130102571
Title Selective Sigma-1 Receptor Ligands.
Representative Drug(s) D0A0DV Drug Info N.A. Click to Show More [1]
2 D0C1YW Drug Info N.A. [1]
3 D0G4GT Drug Info N.A. [1]
4 D0G7GN Drug Info N.A. [1]
5 D0L0CD Drug Info N.A. [1]
Patent ID US20100179111
Title Sigma1 Receptor Ligands and Methods of Use.
Representative Drug(s) D0A0DV Drug Info N.A. Click to Show More [1]
2 D0C1YW Drug Info N.A. [1]
3 D0G4GT Drug Info N.A. [1]
4 D0G7GN Drug Info N.A. [1]
5 D0L0CD Drug Info N.A. [1]
References  Top
REF 1 Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.
REF 2 The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.